Reduced protective efficacy of hepatitis B vaccine among fully vaccinated children in Ethiopia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
02
2023
accepted:
25
06
2023
medline:
10
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Hepatitis B vaccination is recommended for all children at birth within 24 hours or during childhood. This study was aimed to evaluate protective efficacy of hepatitis B vaccine and estimate the sero-prevalence of hepatitis B virus infection among vaccinated children. A community-based cross-sectional study was conducted from March, 2021 to October, 2021 in Debre Markos town. A simple random sampling technique was used to select 165 fully vaccinated children aged 5-12 years old. A serum sample was used to determine hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc), anti-hepatitis B surface antibody titer (anti-HBs) using ELISA. The seroprevalence of HBsAg and anti-HBc anti-body was found to be 4.2% and 4.8% respectively. Of 165 fully vaccinated children, 129 (78.2%) had anti-HBs titer ≥ 10 mIU/ml. Among 129 sero-protected children, 76 (58.9%) were hypo-responders whereas the rest 53 (41.1%) were good responders. Those children within the age group of 5-7 years were 2.9 times (AOR: 2.873, 95% CI: 1.156, 7.141) (P<0.023) more likely to respond to HBV vaccine. Multivariate logistic regression revealed that children who were born from HBV positive mothers (AOR 3.917, 95% CI: 1.456, 5.365, P<0.027) and those who had history of injectable medications (AOR 9.232, 95% CI: 1.503, 11.697, P<0.016) were more likely to be HBsAg positive. Children who had history of hospital admission (AOR 6.973, 95% CI: 1.495, 8.530, P<0.013) were more likely to be anti-HBcAb positive. There was an intermediate prevalence of childhood HBV infection despite being vaccinated suggesting low protective efficacy of hepatitis B vaccine in the study area.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B vaccination is recommended for all children at birth within 24 hours or during childhood.
OBJECTIVE
OBJECTIVE
This study was aimed to evaluate protective efficacy of hepatitis B vaccine and estimate the sero-prevalence of hepatitis B virus infection among vaccinated children.
MATERIALS AND METHODS
METHODS
A community-based cross-sectional study was conducted from March, 2021 to October, 2021 in Debre Markos town. A simple random sampling technique was used to select 165 fully vaccinated children aged 5-12 years old. A serum sample was used to determine hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc), anti-hepatitis B surface antibody titer (anti-HBs) using ELISA.
RESULTS
RESULTS
The seroprevalence of HBsAg and anti-HBc anti-body was found to be 4.2% and 4.8% respectively. Of 165 fully vaccinated children, 129 (78.2%) had anti-HBs titer ≥ 10 mIU/ml. Among 129 sero-protected children, 76 (58.9%) were hypo-responders whereas the rest 53 (41.1%) were good responders. Those children within the age group of 5-7 years were 2.9 times (AOR: 2.873, 95% CI: 1.156, 7.141) (P<0.023) more likely to respond to HBV vaccine. Multivariate logistic regression revealed that children who were born from HBV positive mothers (AOR 3.917, 95% CI: 1.456, 5.365, P<0.027) and those who had history of injectable medications (AOR 9.232, 95% CI: 1.503, 11.697, P<0.016) were more likely to be HBsAg positive. Children who had history of hospital admission (AOR 6.973, 95% CI: 1.495, 8.530, P<0.013) were more likely to be anti-HBcAb positive.
CONCLUSIONS
CONCLUSIONS
There was an intermediate prevalence of childhood HBV infection despite being vaccinated suggesting low protective efficacy of hepatitis B vaccine in the study area.
Identifiants
pubmed: 37418447
doi: 10.1371/journal.pone.0288355
pii: PONE-D-23-03776
pmc: PMC10328307
doi:
Substances chimiques
Hepatitis B Vaccines
0
Hepatitis B Surface Antigens
0
Hepatitis B Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0288355Informations de copyright
Copyright: © 2023 Adugna et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Epidemiol Infect. 2003 Aug;131(1):757-70
pubmed: 12948377
BMC Infect Dis. 2021 Dec 2;21(1):1205
pubmed: 34856942
PLoS One. 2013;8(3):e58029
pubmed: 23533578
Clin Infect Dis. 2011 Jul 1;53(1):68-75
pubmed: 21653306
Int J Cancer. 2012 Jan 15;130(2):245-50
pubmed: 21796634
Vaccine. 2018 Apr 25;36(18):2442-2449
pubmed: 29588118
Vaccine. 2007 Aug 21;25(34):6326-33
pubmed: 17629600
Rev Soc Bras Med Trop. 2012 Mar-Apr;45(2):260-2
pubmed: 22535004
N Engl J Med. 2004 Mar 11;350(11):1118-29
pubmed: 15014185
AIDS. 2005 Sep 23;19(14):1473-9
pubmed: 16135900
Egypt J Immunol. 2014;21(1):13-26
pubmed: 25204041
Indian J Med Res. 2013 Feb;137(2):356-62
pubmed: 23563380
Am Fam Physician. 2010 Nov 15;82(10):1225-9
pubmed: 21121533
Dig Dis Sci. 2011 Nov;56(11):3163-71
pubmed: 21861105
Rev Med Virol. 2014 Nov;24(6):396-406
pubmed: 24956038
J Infect Dev Ctries. 2018 Nov 30;12(11):1002-1008
pubmed: 32012131
Lancet Infect Dis. 2010 May;10(5):338-49
pubmed: 20417416
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
PLoS One. 2015 Dec 30;10(12):e0145209
pubmed: 26716979
Trop Med Int Health. 2006 Oct;11(10):1496-502
pubmed: 17002723
BMC Res Notes. 2011 Feb 09;4:35
pubmed: 21303563
J Infect Dis. 2001 Oct 1;184(7):905-8
pubmed: 11509998
BMC Infect Dis. 2020 Jul 22;20(1):528
pubmed: 32698884
Int J Infect Dis. 2005 May;9(3):139-43
pubmed: 15840454
Mutat Res. 2000 Apr;462(2-3):381-93
pubmed: 10767647
J Med Virol. 2008 Feb;80(2):217-24
pubmed: 18098129
Infection. 2010 Oct;38(5):395-400
pubmed: 20589522
Vaccine. 2014 Jan 3;32(2):217-22
pubmed: 24284410
Can J Gastroenterol. 1998 Jan-Feb;12(1):57-60
pubmed: 9544413
BMC Public Health. 2019 Nov 1;19(1):1433
pubmed: 31675948
J Egypt Public Health Assoc. 2005;80(5-6):495-508
pubmed: 17187739
Bull World Health Organ. 2000;78(8):956-63
pubmed: 10994278
Hepat Res Treat. 2017;2017:2131627
pubmed: 28367327
Kidney Int. 2005 Nov;68(5):2298-303
pubmed: 16221232
World J Hepatol. 2015 May 18;7(8):1064-73
pubmed: 26052395
BMC Pediatr. 2017 Jul 14;17(1):164
pubmed: 28705230
J Hepatol. 2003;39 Suppl 1:S64-9
pubmed: 14708680
Semin Fetal Neonatal Med. 2007 Jun;12(3):160-7
pubmed: 17336170
Am J Public Health. 2012 Feb;102(2):277-84
pubmed: 21940914
Int J Infect Dis. 2015 Nov;40:75-80
pubmed: 26456567
Korean J Intern Med. 2013 Jul;28(4):413-9
pubmed: 23864799